摘要
目的探讨氟伐他汀钠对既往冠心病患者感染衣原体后动脉硬化危险因子的影响。方法选取浙江省舟山医院符合纳入标准且确诊的冠心病史衣原体感染患者58例,按随机数字表法分为对照组和研究组,分别为29例,对照组予以常规治疗,研究组在常规治疗上予以氟伐他汀钠(20 mg/次,1次/天)治疗,共治疗4周为一疗程,于治疗前后采血测定血脂、血管内皮功能、基质金属蛋白酶及炎症因子水平,同时记录2组间不良反应状况。结果相对于对照组,研究组治疗后胆固醇(total cholesterol,TC)、三酰甘油(triglyceride,TG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)及血脂综合指数(lipid comprehensive index,LCI)水平较低,高密度脂蛋白胆固醇(high density lipid-cholesterol,HDL-C)水平较高,可溶性细胞间粘附分子1(soluble intercellular adhesion molecule-1,s I-CAM-1)、内皮素-1(endothelin-1,ET-1)水平较低,NO水平较高,基质金属蛋白酶1(matrix metalloproteinase-1,MMP-1)、基质金属蛋白酶9(MMP-9)及基质金属蛋白酶组织抑制因子-1(tissue inhibitor of metalloproteinase-1,TIMP-1)含量较低,肿瘤坏死因子(tumor necrosis factor-α,TNF-α)、白介素-1β(interleukin 1 beta,IL-1β)、高敏C反应蛋白(high-sensitivity c-reactive protein,Hs-CRP)及IL-6水平较低(P<0.05);所有患者均获得随访,仅为胃肠道轻微不良反应,2组间不良率对比差异无统计学意义。结论氟伐他汀钠能降低冠心病史衣原体感染患者血脂、基质金属蛋白酶水平,改善血管内皮功能及炎症状态,安全性高。
Objective To investigate the effect of fluvastatin sodium on the risk factors of atherosclerosis in patients with previous coronary heart disease. Methods 58 cases meeting the inclusion criteria and diagnosed coronary heart disease history of chlamydial infection were selected and randomly divided into study group and control group,29 cases in each group,the control group were given routine treatment,study group on the basis of conventional treatment of fluvastatin sodium（20 mg pertime,once daily） treatment. A total of 4 weeks treatment for a course,the blood lipid and vascular endothelial function,matrix metalloproteinases and inflammatory factor levels were determined before and after treatment,and adverse reactions were recorded between the two groups. Results Compared with the control group,the total cholesterol（TC）,triglyceride（TG）,low density lipoprotein cholesterol（LDL-C） and lipid comprehensive index（LCI） in study group after treatment were lower,the high density lipid-cholesterol（HDL-C） was higher,the soluble intercellular adhesion molecule-1（s I-CAM-1） and endothelin-1（ET-1） were lower,the NO was higher,matrix metalloproteinase-1（MMP-1）,MMP-9 and tissue inhibitor of metalloproteinase-1（TIMP-1） were lower,and tumor necrosis factor-α（TNF-α）,interleukin 1 beta（IL-1β）,high-sensitivity c-reactive protein（Hs-CRP） and IL-6 were lower（all P〈0. 05）. All patients were followed up,only slight gastrointestinal adverse reaction,there was no significant difference in adverse reactions between the two groups. Conclusion The fluvastatin sodium can reduce the blood lipid,the level of matrix metalloproteinases,improve vascular endothelial function and inflammatory state,with high safety.
出处
《中国生化药物杂志》
CAS
2016年第9期68-71,共4页
Chinese Journal of Biochemical Pharmaceutics
关键词
氟伐他汀钠
冠心病史
衣原体感染
动脉硬化危险因子
fluvastatin sodium
a history of coronary heart disease
chlamydia infection
risk factors of atherosclerosis
